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2. Abbreviation list 
AMPs 
ATCC 
C. pneumoniae 
C. psittaci 
C. trachomatis 
cDNA 
Cys 
DTT 
EB 
ELISA 
FACS 
FITC 
GAG 
Gln 
HEPES 
HRP 
IF 
IFN 
IFU 
IL 
IP- 10 
I-TAC LC-
MSMS 
LPS 
MIF 
MFB 
MIG 
MOMP 
antimicrobial peptides 
American Tissue Culture Corporation 
Chlamydophila pneumoniae 
Chlamydophila psittaci Chlamydia 
trachomatis complementary 
deoxyribonucleic acid 
cysteine 
dithiothreitol 
elementary body 
enzyme-linked immunosorbent assay 
fluorescence-activated cell sorting 
fluorescein isothiocyanate 
glycosaminoglycans 
glutamine 
(2-hydroxyethyl)- 1 -piperazineethanesulfonic acid 
horseradish peroxidase 
immunofluorescence 
interferon 
inclusion forming unit 
interleukin 
interferon-inducible protein- 10 interferon-
inducible T-cell alpha chemoattractant liquid 
chromatography-tandem mass spectrometry 
lipopolysaccharide 
microimmunofluorescence 
mouse fibroblast 
monokine induced by interferon gamma 
major outer membrane protein 
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mRNA 
MW 
NCR 
NK 
OmcB 
PBST 
PCR 
PE 
RB 
RNA SD 
SDS-PAGE 
SPG 
TNF 
messenger ribonucleic acid 
molecular weight nodule-
specific cysteine rich 
natural killer 
outer membrane complex B 
phosphate buffered saline with tween 
polymerase chain reaction 
phycoerythrin 
reticular body 
ribonucleic acid 
standard deviation 
sodium dodecyl sulphate polyacrylamide gel electrophoresis 
sucrose-phosphate-glutamic acid buffer 
tumour necrosis factor 
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3. Introduction 
3.1. Chlamydiaceae 
The family Chlamydiaceae consists of two clinically important genera, Chlamydia and 
Chlamydophila, with three species responsible for human disease: Chlamydia trachomatis (C. 
trachomatis), Chlamydophila psittaci (C. psittaci), and Chlamydophila pneumoniae (C. 
pneumoniae). Other species have been placed into the two genera, but they are uncommon 
human pathogens. 
Chlamydiaceae are obligate intracellular parasites that were once considered viruses because 
they are small enough to pass through 0.45 m filters. However, the organisms have the 
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regions are found in C. psittaci MOMP; in contrast, the C. pneumoniae MOMP is 
homogeneous, and only a single serovar has been described. A second, highly conserved outer 
membrane protein, OMP 2, is shared by all members of the family Chlamydiaceae. This 
cysteine-rich protein is responsible for the extensive disulfide cross-links that provide the 
stability in the EBs (Penttila et al., 2000; Watson et al., 1994). 
The replication of Chlamydiaceae occurs within susceptible host cells (Figure 1). The cycle is 
initiated when the small (300 to 400 nm), infectious EBs become attached to the microvilli of 
susceptible cells, followed by active penetration into the host cell. After they are internalized, 
the bacteria remain within cytoplasmic phagosomes, where the replicative cycle proceeds. If the 
outer membrane of the EBs is intact, fusion of cellular lysosomes with the EB-containing 
phagosome is inhibited, thus preventing intracellular killing. If the outer membrane is damaged 
or the bacteria are inactivated by heat or coated with antibodies, phagolysosomal fusion occurs 
with subsequent bacterial killing. Within 6 to 8 hours after entering the cell, the EBs reorganize 
into the larger (800 to 1000 nm), metabolically active RBs. The Chlamydiaceae are energy 
parasites, because they use the host cell’s adenosine triphosphate for their energy requirements. 
Some strains may also depend on the host to provide specific amino acids. The RBs replicate by 
binary fission, similar to other bacteria; histological stains can readily detect the phagosome 
with accumulated RBs, called an inclusion. Approximately 18 to 24 h after infection, RBs begin 
to reorganize into smaller EBs, and between 48 and 72 h, the cell ruptures and the infectious 
bacteria are released (Murray et al., 2009). 
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Figure 1. Life cycle of Chlamydiae [www.chlamydiae.com] 
3.1.2. Chlamydophila pneumoniae 
C. pneumoniae is a species of Chlamydophila bacteria that causes 10% of community-
acquired pneumonia cases among adults. Until recently it was known as Chlamydia 
pneumoniae, and that name is used as an alternate. Previously the pathogen was known as the 
TWAR agent (Taiwan Acute Respiratory Agent) from the names of the two original isolates - 
Taiwan (TW-183) and an acute respiratory isolate designated AR-39 (Blasi et al., 2009). 
C. pneumoniae causes by far the most common human chlamydial infection, with seropositivity 
in at least 50% of the general population over the age of 20 in the United States and elsewhere 
(Kanamoto et al., 1991; Grayston et al., 1992). Although most of the acute infections with C. 
pneumoniae are probably asymptomatic, they may be frequently associated clinically with 
pneumonia, pharyngitis, sinusitis, and bronchitis (Blasi et al., 2009). Moreover, C. pneumoniae 
has been suggested to be a risk factor for immune-reactive disorders such as adult onset asthma, 
reactive arthritis, and the acute chest syndrome of sickle cell anaemia (Hahn et al., 1991; Miller 
et al., 1991). Chronic infections caused by C. pneumoniae have also been linked to the 
development of heart diseases and atherosclerosis, the diseases which are responsible for the 
greatest morbidity and mortality in Western civilization (Burian et al., 
 10 
2001a; Burian et al 2001b; Rugonfalvi et al., 2002; Heltai et al 2004; Belland et al., 2004). The 
diagnosis of C. pneumoniae infections is difficult. The organisms do not grow in cell lines used 
for the isolation of C. trachomatis, and although C. pneumoniae will grow in HEp-2 cell line, 
this cell line is not used in most clinical laboratories. Detection of C. pneumoniae by nucleic 
acid amplification has long been successful; however, significant interlaboratory variation has 
been reported among laboratories with diverse experience in the use of these assays (Mahony et 
al., 1994). Microimmunofluorescence (MIF) test can be considered the only acceptable test for 
serodiagnosis. The criteria for the diagnosis of acute C. pneumoniae infection is a single IgM 
titre of >1:16 or a fourfold increase in IgG titer. A single increased IgG titre cannot be 
appropriately evaluated. Because IgG antibodies do not appear for 6 to 8 weeks after infection, 
serologic testing has limited value for the diagnosis of an acute infection. 
The administration of macrolides (erythromycin, azithromycin, and clarithromycin), 
doxycycline, or levofloxacin is recommended for the treatment of C. pneumoniae infections, 
although evidence supporting their use is limited. Control of the exposure to C. pneumoniae is 
rather difficult since the bacterium is ubiquitous (Murray et al., 2009). 
3.1.3. Chlamydia trachomatis 
C. trachomatis has three human serotypes. Serovars Ab, B, Ba, or C cause the trachoma, 
an infection of the eyes, which is the leading infectious cause of blindness worldwide. 
Serovariants D-K and L1, L2, L3 cause sexually transmitted diseases, such as urethritis, pelvic 
inflammatory disease, and ectopic pregnancy (D-K), and lymphogranuloma venereum (LGV; 
L1-3). 
C. trachomatis, especially serovars D-K, is of great public health significance because of the 
economic burden of chlamydial infections and the impacts of the untreated (or unsuccessfully 
treated) cases on human reproduction. Cervicitis and urethritis commonly occur in women, and 
about 40% of the untreated cases progress to pelvic inflammatory disease (PID). 20% of the 
PID cases results in infertility, while 18% of the women with this disease experience chronic 
pelvic pain, and 9% may suffer an ectopic pregnancy (Shaw et al., 2011). 
A prominent survey has been carried out by Washington et al. investigating the direct and 
indirect healthcare costs of chlamydial infections in men, and the infections and their sequelae 
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in women (Washington et al., 1985; Randolph and Washington, 1990). Even though this study 
demonstrates the chlamydial infections to represent a substantial economic burden, it is still 
likely to underestimate the full costs of managing chlamydial infections and their consequences. 
At the individual level, C. trachomatis infection can generally be treated effectively with 
antibiotics, though antibiotic resistance appears to be increasing (Shaw et al., 2011). At the 
population level, public health control of the infection is rather problematic. With regard to the 
severe potential consequences of urogenital C. trachomatis infection in women, many countries 
offer screening. A variety of diagnostic methods are available for the detection of asymptomatic 
infections. Economic investigations suggest that the screening of asymptomatic individuals is a 
cost-effective strategy. (Malek, 2001) 
Vaccination, which is currently unavailable, would be the best way to reduce the prevalence of 
C. trachomatis infections, as it would be much cheaper and would have a greater impact on 
controlling C. trachomatis infections worldwide (Hafner et al., 2008, Schautteet et al., 2011, 
Howie et al., 2011). 
Regarding serovars A-C, trachoma is endemic in over 50 countries (Thylefors et al., 1995). 
Worldwide, over 80 million people have active trachoma, over 7 million have trichiasis 
(ingrown eyelashes), and over 1 million have blindness due to corneal scarring (Resnikoff et al., 
2004, Wright et al., 2008). The prevalence of trachoma varies considerably. For example, in 
most countries of the Middle-East, Indian sub-continent, South-East Asia, Latin America and 
Australia, the prevalence of active trachoma has decreased markedly due to the improvements 
in public health. In contrast, in rural areas of North, East and South Africa trachoma is still 
hyperendemic. Sadly, active infection with C. trachomatis is mostly seen in children around 
four to six years; the prevalence in the hyperendemic areas can be 70% (West et al., 2001). 
3.2. Chlamydial persistence and the difficulties in the therapy of chlamydial infections 
Chlamydiae have the ability to cause prolonged and often subclinical infection. In vitro, 
it can be demonstrated that Chlamydiae can enter a latent state under stressful conditions such 
as exposure to interferon (IFN)- or certain antibiotics. This persistent form allows C. 
trachomatis to remain dormant in the host cell, resulting in a long-term relationship 
 with the host. It is known that serological diagnosis of chronic persistent, latent infections can 
be somewhat imprecise because of low detectable levels of specific antibodies. It has previously 
been reported that even very low levels of specific antibodies may be directly associated with a 
persistent infection. How often persistence occurs in vivo is unknown, but it may serve as an 
adaptive survival mechanism for the organism. 
C. trachomatis infections can be effectively treated with antibiotics that are able to pass through 
the cell membranes and thus reach the RBs; cyclines, quinolones and macrolides are widely 
used for this purpose. In the case of pregnant women, amoxicillin is used in the antichlamydial 
therapy (Guaschino and Ricci, 2002). 
Whittington et al. (2001) investigated the chance for therapeutic failures. They noted that 50 of 
792 patients with C. trachomatis genital tract infections remained infected 42 days after 
receiving proper doxycycline or azythromycin treatment. The failure of the anti-chlamydial 
therapy cannot be explained only by re-infection. Several factors were indicated to be 
associated with infection continuation, such as the age of the patient, the renewal of sexual 
intercourse, low compliance, and drug pharmacokinetics and availability at the tissue level. 
However, studies have shown that failure could occur in spite of drug availability. 
According to some studies, chlamydial resistance can have a role in therapy failure. Somani et al. 
published a case report of a pregnant woman and a couple who were respectively infected by C. 
trachomatis serovars E and F. In the therapy, the minimal concentrations of doxycycline, 
ofloxacin and azythromycin required to inhibit these patients' isolates were prominently higher 
than for susceptible control C. trachomatis strains. Based on this work, the authors suggested 
that certain C. trachomatis strains can bear heterotypic resistance (Somani et al., 2000). This 
indicates that the chlamydial population contains both susceptible and resistant organisms. 
Studies on this subject have revealed that only around 1% of the population is multiresistant 
(Jones et al., 1990; Lefevre et al., 1997). The mechanism which can be responsible for 
heterotypic resistance is yet unknown, but persistence can be suggested. C. trachomatis has 
been reported to adopt an intracellular form that is metabolically less active and thus less 
sensitive to antibiotics. This results in a long-lasting association between bacteria and their host. 
 3.3. Chemokines 
Chemokines have molecular masses of 8-10 kDa and show approximately 20-50 % 
sequence homology at the protein level. The proteins also share common gene structures and 
tertiary structures. All chemokines possess a number of conserved cysteine residues involved in 
intramolecular disulfide bond formation, which allows chemokines to be grouped into 4 
families (Figure 2.): alpha- (CXC), beta- (CC), gamma- (XC) and delta- (CX3C) chemokines, 
depending on the presence of conserved NH2-terminal cysteine residues (Baggiolini, 2001). 
 
Figure 2. Structure of chemokine classes 
[http://www.websters-online-dictionary.org/images/] 
The CXC chemokine family is further divided into 2 classes, depending on the presence o 
absence of an NH2-terminal ELR sequence (Glu-Leu-Arg). The ELR-containing CXC 
chemokines (e.g. interleukin-8) chemoattract neutrophils, while the non-ELR CXC chemokines 
chemoattract lymphocytes. The monokine induced by IFN-  ( MI G/CX CL9 ) ,  the 
 epithelial cells and giant cells (Park et al., 2002). 
The binding of ligands to the receptors results in the activation and recruitment of the receptor 
bearing cells to the sites of inflammation. MIG/CXCL9 seems to have a multifaceted role in 
various immunological processes, such as autoimmune diseases, transplantational immunity, 
and neuroimmunity. It has also been revealed, that MIG/CXCL9 plays a role in the inhibition of 
fibrosis and angiogenesis, mainly in pancreatitis, and chronic hepatitis of various origins (Shen 
et al., 2013; Liang et al., 2012; Sahin et al., 2012). MIG/CXCL9 and other CXC chemokines 
(IP-10/CXCL10 and I-TAC/CXCL1 1) additionally possess antibacterial activity in vitro (Cole 
et al., 2001). 
Several papers have been published regarding the antimicrobial effects of MIG/CXCL9 against 
Escherichia coli, Listeria monocyto genes, Streptococcus pyo genes, Streptococcus 
pneumoniae, Neisseria gonorrheae, Fine goldia magna, Bacillus anthracis, Porphyromonas 
gingivalis, and Mycobacterium tuberculosis (Cole et al., 2001; Egesten et al., 2007 and 2009; 
Eliasson et al., 2007 and 2010; Linge et al., 2008; Higaki and Morohashi, 2003; Murdoch, 
2008; Karlsson et al., 2007 and 2009; Crawford et al., 2009 and 2010; Jauregui et al., 2013; Bai 
et al., 2010; Balogh et al., 2011; Handel et al., 2005). However, the function of MIG/CXCL9 in 
C. pneumoniae infection has not been investigated thoroughly prior to our work. Skwor et al. 
(2008) found that chemokine protein levels for CCL1 1, CCL8, MIG/CXCL9, and CCL2 were 
elevated in chronic scarring trachoma when compared with age and sex-matched controls. Mice 
deficient in the receptor for type I IFNs (IFNAR-/-) exhibited enhanced CD4 T cell recruitment 
to the cervical tissues, which was associated with an increased expression of MIG/CXCL9 in 
the genital secretion of IFNAR-/-mice, but not with the expression of CXCL10, which was 
reduced in the genital secretion of these mice (Nagarajan et al., 2008). In a mouse model after 
C. trachomatis infection, supernatants from upper genital tract homogenates contained 
significantly higher levels of MIG/CXCL9, CXCL10, and CCL5 than those in the lower genital 
tract (Maxion and Kelly, 2001). 
3.4. Antimicrobial peptides 
Antimicrobial peptides (AMPs), natural antibiotics produced by nearly all organisms 
from bacteria to plants and animals, are crucial effectors of innate immune systems, with 
different spectra of antimicrobial activity and with the ability to perform rapid killing. To date, 
more than 800 AMPs have been discovered in various organisms, including 270 in 
 plants. It has become clear in recent years that these peptides are able not only to kill a variety 
of pathogens, but also to modulate immune responses in mammals. However, their modes of 
action are poorly understood. In some species these peptides serve as the primary antimicrobial 
defence mechanism, whereas in others they serve as an adjunct to existing innate and adaptive 
immune systems (Brogden and Brogden, 2011). Cationic AMPs interact with negatively 
charged microbial membranes and permeabilize the membrane phospholipid bilayer, resulting in 
lysis and the death of microbes (Powers and Hancock, 2003; Hancock and Rozek, 2002). In view 
of their rapid and broad-spectrum antimicrobial properties, interest has emerged in AMPs as 
potential antibiotic pharmaceuticals to combat infections and microbial drug resistance (Hadley 
and Hancock, 2010; Capparelli et al., 2012). 
Most plant AMPs are cysteine cluster proteins. This group includes major plant immunity 
effectors such as defensins, and also symbiotic peptides, including the nodule-specific cysteine 
rich (NCR) peptides, which are produced in Medicago-Sinorhizobium meliloti symbiosis and 
provoke irreversible differentiation of the endosymbiont. The NCR family is composed of about 
500 divergent peptides in Medicago truncatula (Mergaert et al., 2003; Alunni et al., 2007; Nallu 
et al., 2013). Some cationic NCRs have been shown to possess genuine antimicrobial activities 
in vitro, killing various Gram-negative and Gram-positive bacteria highly efficiently (Tiricz et 
al., 2013). 
The present study was designated to improve our current understanding of the pathological 
immune response to infection with chlamydiae and to find new natural compounds which have 
anti-chlamydial activities and might serve as alternative anti-microbial agents. 
 4. Aims 
Our aims were the following 
1. to detect whether C. pneumoniae can induce the production of CXCL chemokines in 
vitro and in in vivo mouse model; 
 
2. to investigate the effect of co-treatment with C. pneumoniae and IFN-on the 
expression of MIG/CXCL9 in different cell types; 
3. to study the anti-chlamydial activity of CXCL chemokinesin vitro and to reveal the 
binding partner of MIG/CXCL9 on Chlamydia EBs; 
4. to investigate the anti-chlamydial activity of plant peptides; 
5. to find the chlamydial ligand responsible for the binding of NCR proteins. 
 5. Materials and methods 
5.1. C. pneumoniae experiments 
5.1.1. Inoculum preparation and culturing ofC. pneumoniae from the lungs 
C. pneumoniae strain TWAR CDC/CWL-029 [American Type Culture Collection 
(ATCC)] and a cardiovascular strain CV6, isolated from an atheroma of a patient with coronary 
artery disease (Maass et al., 1998), were propagated on HEp-2 cells (Dr Jacobs, National 
Institute for Biological Standards and Control, London, UK) in Modified Eagle Medium 
(Sigma, Saint Louis, Missouri, USA), supplemented with 10% fetal calf serum, 0.5% glucose, 0.3 
mg L-glutamin e, 4 mM HEPES an d 25 g of gentamycin/ml. Two hours after 
 5.1.2. Mice and infection conditions 
Eight-week-old female Balb/c mice were obtained from the Charles River Laboratory. 
The mice were fed a regular mouse chow diet ad libitum and housed under biosafety level 2 
conditions. Before infection, mice were mildly sedated with an intraperitoneal injection o 200 l 
of sodium pentobarbital (7.5 mg/ml). They were then infected intranasally with 5x105 IFU of C. 
pneumoniae (CWL029) in 25 l of SPG. Uninfected mice were used as controls. After 
inoculation, 7 mice were anaesthetized and sacrificed on each of days 1, 2, 4, 7, 14 and 28. Sera 
were taken by cardiac puncture. The lungs were removed, cut up with scissors and then 
homogenized with seesand (acid purified; Fluka Chemie AG, Buchs, Switzerland) in a mortar 
with a pestle for 2 min (each sample). One half of the homogenized lungs was processed for 
real-time PCR, while the other half was re-suspended in 1 ml of SPG for the detection of viable 
C. pneumoniae, and for cytokine and chemokine measurements. 
All experiments fully complied with the University of Szeged Guidelines for the Use of 
Laboratory Animals. 
5.1.3. In vitro induction of MIG/CXCL9 
J774A mouse macrophage cells (ATCC) and in-house-prepared mouse fibroblast 
cultures were grown in 24-well tissue culture plates in Modified Eagle Medium (Sigma) 
supplemented with 10% foetal calf serum, 0.5% glucose, 0.3 mg of L-glutamine/ ml, 4 mM 
HEPES and 25 g of gentamycin/ml. The semiconfluent tissues were infected with C. 
pneumoniae strain CWL029 or cardiovascular strain CV6 at a multiplicity of infection (m.o.i.) 
of 0.5 IFU or treated with the same volume of heat-inactivated EBs of the C. pneumoniae strains 
alone, or in the presence of different concentrations (10, 100 or 1000 IU/ml) of recombinant 
IFN-(Millipore, Bedford, Maryland, USA). Untreated cells served as controls. Supernatants of 
the treated cells were harvested after 24, 48 or (in some experiments) 72 h. Samples were 
centrifuged and stored at -80 °C un til use. MIG/CXCL9 concentrations of the samples were 
determined with the Quantikine mouse CXCL9/MIG kit (R&D Systems, Minneapolis, USA). 
 5.1.4. Measurement of the in vitro antibacterial activity of MIG/CXCL9, IP-10/CXCL10 
and I-TA C/CXCL11 
EBs of C. pneumoniae strain CWL-029 (4x104 IFU/ml) were incubated with 
recombinant MIG/CXCL9 (PeproTech London, UK) at various concentrations (10, 5, 2.5 or 
1.25 g/ml) or IP-10/CXCL10 or I-TAC/CXCL1 1 (PeproTech) (10 g/ml) in SPG for 2 h at 37 
°C. As controls, C. pneumoniae CWL-029 was also incubated either in buffer alone or mixed 
with heat-treated (90 C, 30 min) MIG/CXCL9 (10 g/ml). The time course of the anti-
chlamydial effect of MIG/CXCL9 was tested after incubation periods of 0.25, 0.5, 1 and 2 h. 
To quantitate the anti-chlamydial effects of MIG/CXCL9, IP-10/CXCL10 and I - TAC/CXCL1 
1, HEp2 cells were seeded in 24-well tissue culture plates with 1 3-mm cover glasses. After 24 
h, the confluent cells were infected with MIG/CXCL9-treated C. pneumoniae CWL029 or the 
controls. After 48 h, the cells were fixed with acetone at -20 °C for 10 min. Fixed cells on 
cover glasses were stained as mentioned above. 
5.1.5. Cytokine and chemokine measurements on the lungs 
The supernatants of the lung homogenates and the sera were clarified by centrifugation (5 
min, 12 000îg) and were assayed for IFN- content with the OptEIA ELISA set (BD Biosciences 
Pharmingen San Diego, CA, USA). The concentration of MIG/CXCL9 was determined using 
Quantikine mouse CXCL9/MIG kit (R&D Systems). The sensitivities of the IFN- and 
MIG/CXCL9 measurements lay in the ranges 125-1000 pg/ml and 31.2-2000 pg/ml, 
respectively. The clarified supernatants and sera were tested in duplicate in accordance with the 
manufacturer’s instructions. 
5.1.6. mRNA extraction and real-time PCR 
Total RNA was extracted from the lung suspensions with the TRI Reagent (Sigma). 
First-strand cDNA was synthesized from 2 g of RNA by using reverse transcriptase, 
Superscript III (Invitrogen Carlsbad, Ca, USA) and 20 pM random primer in 20 l of reaction 
buffer. The synthesized first-strand cDNAs were amplified by quantitative real-time PCR, 
using 20 pM primer pair, with SYBR~ Green JumpStartTM Taq ReadyMixTM (Sigma) in a 
  
total volume of 20 l. Thermal cycling was initiated with a first denaturation step of 5 min at 95 
°C, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. The mouse MIG/CXCL9-
specific primers were as follows: MIG/CXCL9 sense 5’-ACG TAG GTT TCG AGA CCA 
GGG ATT-3’, MIG/CXCL9 antisense 5’-CAA CAC CAA GTG TTC TGC CAC CAA-3’; 
IP10/CXCL10 sense 5'-TGG CTA GTC CTA ATT GCC CTT GGT-3', IP10/CXCL10 
antisense 5'-TCA GGA CCA TGG CTT GAC CAT CAT-3'; ITAC/CXCL11 sense 5'-TAC 
CCG AGT AAC AGC TGC GAC AAA-3', ITAC/CXCL1 1 antisense 5'-TAT GAG GCG 
AGC TTG CTT GGA TCT-3'. The real-time PCR amplification data were analysed by means 
of the Roche Molecular Biochemicals LightCycler Software version 3.5. The lowest cycle 
number at which the various transcripts were detectable, referred to as the threshold cycle (Ct), 
was compared with that of ß-actin, the difference being referred to as Ct. The relative 
expression level was given as 2-( Ct) ,  where Ct=Ct for the experimental sample minus 
t for the control sample. 
5.1.7. Detection of MIG/CXCL9 -binding to Chlamydia EBs by FACS 
Chlamydia EBs (1x106 IFU) were treated with 10 g of MIG/CXCL9 containing PBS for 
2 h at 37 °C. After washing, the cells were stained with phycoerythrin(PE)-labelled anti-
MIG/CXCL9 polyclonal antibody (R&D Systems) for 30 min at 4 °C. As controls, untreated 
and unstained, and untreated PE-labelled anti-MIG/CXCL9-stained cells were used. Cells were 
analysed with FACS StarPlus (Becton Dickinson) device. 
5.1.8. Far-Western blot assay for identification of MIG/CXCL9-binding C. pneumoniae 
proteins 
Concentrated C. pneumoniae CWL-029 EBs (1,75x 105 IFU) (prepared as described 
earlier) and a mock preparation were heated at 95 °C for 5 min in sample buffer, and 
polyacrylamide gel electrophoresis was performed (Laemmli, 1970). The proteins were 
separated by 10% SDS polyacrylamide gel in duplicate, and half of the gel carrying the 
separated proteins of the C. pneumoniae or the mock samples was blotted onto a 
polyvinylidene difluoride membrane (SERVA, Heidelberg, Germany). The membrane was 
blocked overnight at 4 °C with PBS containing 5% skimmed milk and 0.05% Tween 20. The 
 
 membrane was probed with a buffer [1% bovine serum albumin in PBS with 0.05% Tween 20 
(PBST)] containing 10 g/ml MIG/CXCL9 (PeproTech) for 2 h. After washing 3 times with 
PBST, the filter was incubated with HRP-conjugated anti-MIG/CXCL9 IgG (R&D Systems). 
A control lane with separated C. pneumoniae EBs was also incubated with HRP-conjugated 
anti-MIG/CXCL9 without prior treatment with MIG/CXCL9. Following 3 further washings the 
colour was developed by using diaminobenzidine tetrahydrochloride (Sigma) with hydrogen 
peroxide in 10 mM Tris at pH 7.5. The second half of the gel with the separated proteins of the 
C. pneumoniae or the mock preparation was stained with Coomassie blue (Rosenfeld et al., 
1992). 
5.1.9. Identification of proteins by mass spectrometry 
The gel slices containing the polypeptides of the concentrated C. pneumoniae EBs 
corresponding to proteins showing MIG/CXCL9 positivity in the blotting assay were cut out 
from the gel and analyzed by mass spectrometry. Briefly, protein bands were diced and washed 
with 25 mM NH4HCO3 in 50% (v/v) acetonitrile/water. Disulphide bridges were reduced with 
dithiothreitol (DTT), and free sulphydryls were alkylated with iodoacetamide. Proteins were 
digested with modified porcine trypsin (Promega Madison, WI, USA) for 4 h at 37 °C. Samples 
were analyzed on LC-MSMS (liquid chromatography-tandem mass spectrometry) instruments. 
The LC-MSMS raw data were converted into a Mascot generic file with Mascot Distiller 
software (v2. 1.1.0). The resulting peak lists were searched by using the Mascot Daemon 
software (v2.2.2) against the NCBI non-redundant database without species restriction (NCBInr 
20080718, 6833826 sequences). Monoisotopic masses with a peptide mass tolerance of ±0.6 Da 
and a fragment mass tolerance of 1 Da were submitted. Carbamidomethylation of Cys was set 
as a fixed modification and acetylation of protein N - termini, methionine oxidation, and 
pyroglutamic acid formation from peptide N-terminal Gln residues were permitted as variable 
modifications. Acceptance criteria were at least 2 individual peptides with a minimum peptide 
score of 55 per protein. 
 5.1.10. Statistical analysis 
Statistical analysis of the data was carried out with GraphPad Prism 5 software, using 
the Wilcoxon-Mann-Whitney two-sample test. Differences were considered significant at 
p<0.05. 
5.2. C. trachomatis experiments 
5.2.1. Inoculum preparation 
C. trachomatis Serovar D (ATCC~VR-885™) was propagated on HeLa cells as 
described earlier (Caldwell et al., 1981). The partially purified and concentrated EBs were 
aliquoted and stored at -80 °C until use. A mock preparation was prepared from an uninfected HeLa cell 
monolayer processed in the same way as the infected cells. The titre of the infectious EBs was 
determined by indirect immunofluorescence assay. Serial dilutions of the EB preparation were 
inoculated onto tissue culture monolayers and, after a 48-h culture, cells were fixed with 
acetone and stained with murine monoclonal anti-Chlamydia LPS antibody (AbD Serotec, 
Oxford, UK) and FITC-labelled secondary anti-mouse IgG (Sigma). The number of inclusions 
was counted under a UV microscope, and the titre was expressed in inclusion forming units/ml 
(IFU/ml). 
5.2.2. Measurement of in vitro antibacterial activity of NCR peptides 
First, the toxicity of the NCR peptides was tested on non-infected HeLa cells in the 
highest concentration (10 g/ml) used during our experiments. The toxic peptides were excluded 
from the further experiments. 
EBs of C. trachomatis D (4 î 104 IFU/ml) were incubated with chemically synthesized mature 
NCR030 (AFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR pI=10,37); NCR044 
(AFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR pI=10,32); NCR055 
(VNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR pI=9,21); NCR095 
(ELVCDTDDDCLKFFPDNPYPMECINSICLSLTD pI=3,62); NCR1 37 
(MTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK pI=9,7); NCR1 68 
(YPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT pI=3,61); NCR1 69 
  
(EDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK pI=8,45); NCR 183 
(ITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR pI=10,1); NCR192 
(MKNGCKHTGHCPRKMCGAKTTKCRNNKCQCVQL pI=9,54); NCR247 
(RNGCIVDPRCPYQQCRRPLYCRRR pI=10,15); or NCR280 
 
(MRVLCGRDGRCPKFMCRTFL pI=9,8) (Proteogenix Oberhausbergen, France) at various 
concentrations (10, 5, 2.5, or 1.25 g/ml) in sucrose-phosphate-glutamic acid buffer (SPG) for 
 7.5. The second half of the gel with the separated proteins of C. trachomatis or the mock 
preparation was stained with PageBlue Protein Staining Solution (Fermentas). 
5.2.4. Identification of proteins by mass spectrometry 
The gel slices containing the polypeptides of the concentrated C. trachomatis EBs 
corresponding to proteins exhibiting NCR247 positivity in the blotting assay were cut ou from 
the gel and analyzed by mass spectrometry. The proteins were identified as mentioned above in 
section 5.1.9. 
 
5.2.5. Detection of NCR peptide binding to Chlamydia EBs by FACS Chlamydia EBs (1 î 106 
IFU) were treated with 1 g of FIT 
 6. Results 
6.1. C. pneumoniae experiments 
6.1.1. C. pneumoniae infection induces CXC chemokine expression at mRNA and protein 
levels in vivo in Balb/c mice 
To investigate the production of ELR-negative CXC chemokines in C. pneumoniae 
infection, Balb/c mice were inoculated intranasally withC. pneumoniae CWL-029. On day 1, 2, 
4, 7, 14 or 28 after infection, the mice were sacrificed and the lungs were collected for the 
determination of C. pneumoniae titres, MIG/CXCL9, IP-10/CXCL10 and I-TAC/CXCL1 1 
mRNA and MIG/CXCL9 and IFN- protein in the individual lungs. 
In previous studies, culturable C. pneumoniae was demonstrated 14 days after primary infection 
in Balb/c mouse lungs (Kis et al., 2008). In our experiment, the infectious bacterial titres were 
below the level of detectability at 24 h after infection, but had increased to 5.21x104 IFU/lung 
by day 2. The peak titre of C. pneumoniae was measured on day 7, at 1.8x106 IFU/lung, and on 
day 14 after infection, the titre had decreased to 6.15x 103 IFU/lung (Figure 3A). 
The expression of MIG/CXCL9 mRNA was increased as early as on day 1, but the highest 
level of expression (156-fold) was detected on day 7 after infection (Figure 3B). The 
expression of IP-10/CXCL10 and I-TAC/CXCL1 1 mRNA was observed from the first day, 
but, in contrast with MIG/CXCL9 expression, peaked on day 4 at 85-fold and 579-fold, 
respectively (Figure 3C,D). The kinetics of production of MIG/CXCL9 protein correlated with 
the mRNA expression: it was increased from day 1, with the highest concentration on day 7 
(Figure 3E). MIG/CXCL9 was also detected in the sera on days 7 and 14 (360±124 pg/ml and 
798±252 pg/ml, respectively). The concentration of IFN- , the main in ducer of MIG/CXCL9 
expression, was increased in the lungs during the infection, with a peak level of 12.5 ng/ml on 
day 7 (Figure 3F). 
  
 
 
Figure 3. (A) Recovery of culturable C .  p n e u mo n i a e  from the lungs of mice after C .  p n eu m o n i a e  CWL-029 
infection. Lung homogenates were inoculated onto HEp-2 cell monolayers and chlamydial inclusions were 
detected by indirect immunofluorescence, using LPS-specific monoclonal and FITC-labelled secondary antibodies. 
Expression of MIG/CXCL9 (B), IP-10/CXCL10 (C), and I-TAC/CXCL1 1 (D) in the lungs of infected mice. Total 
RNA extracted from the lungs was analysed by quantitative real-time PCR with the use of sp ec i f i c  p r i mers .  Da t a  
a re  n o rma l i zed  fo r  ß -actin RNA content and plotted as fold change over the results for uninfected mice. IFN- (E) 
and MIG/CXCL9 (F) production in the lungs of mice infected with C .  p n e u mo n i a e .  Lung homogenates were 
tested by using IFN- and MIG/CXCL9 ELISA kits according to the manufacturer's instructions. Bars denote 
 
 
 means and SDs of the results on 7 mouse lungs. 
 6.1.2. C. pneumoniae induces MIG/CXCL9 in in vitro cell cultures 
To clarify whether C. pneumoniae is capable of inducing MIG/CXCL9 production in vitro, J774A 
mouse macrophage cells and mouse fibroblast tissue cultures were infected with C. pneumoniae CWL-029 
strain, and the supernatants of the cells were tested by MIG/CXCL9-ELISA. After 24 h, no MIG/CXCL9 
production was observed in either case (Figure 4A). However, C. pneumoniae induced MIG/CXCL9 
secretion by the mouse fibroblasts from day 2 of in fection (122.7±22.3 pg/ml) (Figure 4B), and J774A 
cells produced MIG/CXCL9 from day 3 after infection (156.9±56.7 pg/ml) (data not shown). The heat-
inactivated Chlamydia preparation also induced the production of MIG/CXCL9, at a level comparable to 
that for viable Chlamydia in both cell lines. During in vivo infection with C. pneumoniae, a large quantity 
of IFN-the main inducer of MIG/CXCL9) was detected in the mouse lungs. When the influence of IFN- 
on C. pneumoniae-induced MIG/CXCL9 production was investigated in in vitro cultures, co-treatment 
with different quantities of recombinant mouse IFN- (10, 100 or 1000 U/ml) and C. pneumoniae at a m.o.i. 
of 0.5 caused a dose-dependent increase in MIG/CXCL9 secretion in both cultures from day 1. Co-
treatment of the mouse fibroblasts with C. pneumoniae and 10, 100 or 1000 U/ml of IFN-caused 51.8-, 27- 
and 25.8-fold increases in MIG/CXCL9 production, respectively, after 24 h relative to that 
evoked by treatment with the same quantities of IFN- alone. The enhancement of the 
secretion of MIG/CXCL9 was similar when the co-treatment was carried out with heat-
inactivated C. pneumoniae and different quantities of IFN-10 ,  100 or 1000 U/ml): 75-, 31.5- and 25.8-
fold increases were observed after 24 h as compared with the increase induced by the different quantities 
of IFN- alone. Co-treatment of the J774A cells with C. pneumoniae and 10, 100 or 1000 U/ml of IFN- led 
to 21.6-, 7.4- and 10.8-fold increases in MIG/CXCL9 production, respectively, after 24 h in comparison 
with that evoked by the treatment with the same quantities of IFN- alone. The elevation of the secretion of 
MIG/CXCL9 was also more pronounced, as in the case of the elevation of mouse fibroblasts when the co-
treatment was carried out with heat-inactivated C. pneumoniae and different quantities of IFN- 10, 100 or 
1000 U/ml): 25.3-, 8.7- and 13.3-fold increases, respectively, after 24 h relative to the data for IFN- alone. 
Under all of the conditions mentioned above, the mouse fibroblasts produced significantly more 
MIG/CXCL9 than did the J774A (p<0.05; 
 
 Figure 4A,B). Similar results were seen under the conditions described above in both cell 
cultures after 48 h (Figure 4B). 
 
Figure 4. C .  p n e u m o n i a e -induced MIG/CXCL9 production in J774A and mouse fibroblast (MFB) cells in the 
presence of IFN-. The cells were grown in 24-well tissue culture plates. The semi-confluent tissues were 
 
 
 
 
 infected with C .  p n e u m o n i a e  strain CW-L029 at a m.o.i. of 0.5 IFU, or were treated with the same amount of heat-
inactivated C .  p n e u m o n i a e  alone, or in the presence of different quantities of IFN- (10, 100 or 1000 U/ml). 
Untreated J774A and MFB cells served as controls. Supernatants of the 3 biological replicates were taken afte 24 
(A) and 48 (B) h. Samples were clarified by centrifugation, and the MIG/CXCL9 concentrations in th samples were 
detected with the ELISA kit accordingto the manufacturer's instruction. BD: below detectability All the data are 
representative of three separate experiments; SDs are shown. MFB cells produced a significantl higher level of 
MIG/CXCL9 than J774A cells in all combinations and at both time points (p <0.05). 
A separate experiment revealed that the viable cardiovascularC. pneumoniae strain CV6 and its 
inactivated form also induced MIG/CXCL9 production in the mouse fibroblasts (156±34 and 
187±67 pg/ml, respectively) after 48 h and also in the J774A cells (124±35 and 1 41±47 pg/ml, 
respectively) after 72 h (data not shown). 
6.1.3. Effect of MIG/CXCL9 on C. pneumoniae infectivity 
To determine whether MIG/CXCL9 has anti-chlamydial activity, in vitro bactericidal 
tests were carried out. Co-incubation of C. pneumoniae with recombinant mouse MIG/CXCL9 
demonstrated a dose-dependent antibacterial activity of MIG/CXCL9 againstC. pneumoniae. At 
a MIG/CXCL9 concentration of 10 g/ml, the number of viable C. pneumoniae inclusions was 
reduced by 98.4%, and at the lowest MIG/CXCL9 concentration tested (1.25 g/ml) a reduction 
of 79% was detected. The heat-treated recombinant MIG/CXCL9 did not exert an anti-
chlamydial effect (Figure 5A). The experiments relating to the time course of the antibacterial 
effect of MIG/CXCL9 demonstrated a significant reduction (50%) in the number of viable 
Chlamydia inclusions after a 15-min co-incubation of MIG/CXCL9 and the Chlamydia EBs 
(Figure 5B). No anti-chlamydial effect was observed when other ELR-negative chemokines, IP-
10/CXCL10 and I-TAC/CXCL1 1, were co-incubated with C. pneumoniae at a concentration of 
10 g/ml (data not shown). 
 Figure 5. Concentration and time dependences of the anti-chlamydial effect of MIG/CXCL9. C .  p n e u mo n i a e  
CWL-029 at 4x104 IFU/ml was incubated with different quantities of recombinant MIG/CXCL9 for 2 h at 3 7 °C (A). 
C .  p n eu m o n i a e  was co-incubated with MIG/CXCL9 (5 g/ml) for 0, 15, 30, 60 or 120 min (B). The infectivity of 
the MIG/CXCL9-treated C.  p n eu mo n i a e  was determined by inoculating the mixture onto confluent HEp-2 cells on 
cover glasses. After a 24-h incubation, the fixed cells were stained with anti-chlamydia LPS antibody and the 
number of inclusions was counted under a UV microscope. All the data are representative of three separate 
experiments. 
6.1.4. Identification of the chlamydial ligand responsible for MIG/CXCL9 binding 
The concentrated C. pneumoniae EB preparation and the mock control preparation were 
separated by SDS-PAGE. After blotting, the membranes were probed with recombinant mouse 
MIG/CXCL9 and incubated with HRP-conjugated anti-MIG IgG. The control lane with 
Chlamydia EBs was stained with HRP-conjugated anti-MIG/CXCL9 IgG without incubation 
with MIG/CXCL9. The recombinant mouse MIG/CXCL9 was bound to 60 and 30 
 
 
 
 kDa protein bands in the Chlamydia lysate (Figure 6A). The recombinant mouse MIG/CXCL9 
did not react with the mock lysate, and the Chlamydia EB lysate did not react with the HRP-
conjugated anti-MIG/CXCL9. The gel slices containing the corresponding polypeptides of the 
concentrated C. pneumoniae EBs associated with the recombinant mouse MIG/CXCL9 were 
cut out from the gel and analysed by liquid chromatography-tandem mass spectrometry (LC-
MSMS) in the Biological Research Centre, Hungarian Academy of Sciences, Szeged. Three 
kinds of chlamydial proteins were indicated by LC-MSMS and confirmed by post source decay 
analysis. The identified proteins included two forms of the 60 kDa cysteine-rich protein (also 
named OmcB/Omp2), which has been shown to be a chlamydial EB surface component to 
which heparin molecules can anchor (Stephens et al., 2001). Besides the 60 kDa whole form, a 
30 kDa truncated form of the 60 kDa cysteine-rich protein (OmcB/Omp2) was identified. A 
third 60 kDa protein was identified as the putative GroEL protein of C. pneumoniae (Table 1) 
(Figure 6B). 
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AAD20337 
    
 
C .  p n e u mo n i a e  
(~ 30 kDa)      
 
Table 1. LC-MS/MS analysis of proteins combined with MIG/CXCL9 identified by SDS–PAGE separation. Band 
numbers refer to the gel bands shown in Figure 6. MW is calculated for the full sequence listed in the database and 
may not reflect the actual size of the protein. 
  
 
 
 
 
Figure 6. Interaction of MIG/CXCL9 and C .  p n e u mo n i a e  EBs. Far-Western blot analysis for identification of the 
chlamydial ligands responsible for MIG/CXCL9 binding. Concentrated C.  p n eu m o n i a e  and mock control 
preparations were separated by SDS-PAGE. After blotting, the membrane was probed with recombinant mouse 
MIG/CXCL9 and incubated with HRP-conjugated anti-MIG IgG (lane 1: molecular weight marker, lane 2: mock 
preparation, lane 3: Chlamydia EBs treated with MIG/CXCL9 and HRP-conjugated anti-MIG/CXCL9, and lane 4: 
Chlamydia EBs treated with HRP-conjugated anti-MIG/CXCL9 only (A). Identified MIG/CXCL9-binding 
proteins of C .  p n eu m o n i a e .  Peptide fragments that match the defined protein sequences are underlined (B). 
 To show that the MIG/CXCL9 is able to bind to the native EBs, a FACS analysis was carried 
out. Figure 7B reveals that the Chlamydia EBs interact with MIG/CXCL9 as EBs incubated 
with MIG/CXCL9 were readily detected after staining with PE-conjugated anti-MIG/CXCL9 
IgG. Chlamydia EBs untreated with MIG/CXCL9 were not stained with PE-conjugated anti-
MIG/CXCL9 IgG (Figure 7C). 
 
Figure 7. FACS analysis for the detection of MIG/CXCL9 binding to wholeC  p n e u m o n i a e  EBs. Untreated and 
unstained Chlamydia EBs (A). MIG/CXCL9 protein-treated and PE-labelled anti-MIG/CXCL9-stained C .  
p n e u m o n i a e  EBs (B). Chlamydia EBs stained with PE-labelled anti-MIG/CXCL9 antibody (C). 
 6.2. C. trachomatis experiments 
6.2.1. Anti-chlamydial effect of plant peptides. 
To determine whether they possess anti-chlamydial activity, 11 NCR peptides (NCR030, 
NC0R44, NCR055, NCR095, NCR137, NCR168, NCR169, NCR183, NCR192 NCR247 and 
NCR280) were co-incubated individually with C. trachomatis EBs at 10 g/ml for 2 h at 37 °C. 
Coun ting of the number of viable C. trachomatis inclusions demonstrated that 7 of the 11 
peptides (NCR044, NCR055, NCR095, NCR183, NCR192, NCR247 and NCR280) were 
effective killers of C. trachomatis in vitro, while NCR030 and NCR168 displayed weaker 
activity, and NCR137 and NCR169 did not exert an anti-chlamydial effect (Figure 8A). C. 
trachomatis inclusions were then treated for 2 h with concentrations of the peptides ranging 
from 1.25 g/ml to 10 g/ml (Figure 8B). NCR044, NCR055 and NCR183 
  
 
 
Figure 8. Concentration and time dependences of the anti-chlamydial effects of NCR peptides.C.  t rachomat i s  at 
4x104 IFU/ml was incubated with 10 g / m l  o f  s y n t h e t i c  N CR  p ep t i d e  f o r  2  h  a t  3 7  ° C  (A ) .C .  t ra ch o ma t i s  EBs 
 were incubated with different quantities of synthetic NC R  p ep t i d e s  fo r  2  h  a t  3 7  °C  (B )  C.  t racho mat is  was co-
incubated individually with different NCR peptides (5 g/ml) for 0, 15, 30, 60 or 120 min (C). The infectivity of the 
NCR peptide-treated C.  t rachomat i s  was determined by inoculating the mixture onto confluent HeLa cells on cover 
glasses. After a 24-h incubation, the fixed cells were stained with anti-chlamydia LPS antibody and the number of 
inclusions was counted under a UV microscope. All the data are representative of three separat experiments. 
6.2.2. Identification of the chlamydial ligand responsible for NCR247 binding 
Further investigations were carried out with NCR247, which displayed antichlamydial 
activity in the previous tests. 
To identify the chlamydial ligand responsible for NCR peptide binding, concentrated C. 
trachomatis EB preparations and mock control preparations were separated by SDS-PAGE. 
After blotting, the membranes were probed with synthetic NCR247 peptide and incubated with 
anti-NCR247 IgG, and then with HRP-labelled anti-rabbit antibody. The control lane with 
Chlamydia EBs was stained with anti-NCR247 IgG and HRP-labelled anti-rabbit antibody 
without incubation with synthetic NCR247 peptide. The synthetic NCR247 peptide was bound 
to a 60-kDa protein band in the Chlamydia lysate (Figure 9A, lane 4). The synthetic NCR247 
did not react with the mock lysate (lane 2), and the Chlamydia EB lysate did not react with the 
HRP-conjugated anti-rabbit antibody (lane 3). The gel slice containing the corresponding 
polypeptide of the concentrated C. trachomatis EBs associated with the synthetic NCR247 
peptide was cut out from the gel and analyzed by LC-MSMS. A 60 kDa putative GroEL protein 
of Chlamydia was indicated by LC-MSMS and confirmed by post source decay analysis 
(Figure 9B). 
  
Figure 9. Interaction of NCR247 peptide and C. trachomatis EBs. Far-Western blot analysis of the chlamydial 
ligands responsible for NCR247 peptide binding. (A) Concentrated C. trachomatis and mock control preparations 
were separated by SDS-PAGE. After blotting, the membrane (lane 2,4) was probed with synthetic NCR247 peptide 
and incubated with anti-NCR247 IgG and HRP-labelled anti-rabbit antibody. (lane 1-molecular weight marker, lane 
2 - mock preparation, lane 4 - Chlamydia EBs lysate). A control lane (lane 3) with separated C. trachomatis EBs 
was also incubated with anti-NCR247 and HRP-conjugated anti-rabbit antibody without prior treatment with the 
NCR247 peptide. Identification of the C. trachomatis proteins by LCMSMS (B). Peptide fragments that match the 
defined protein sequences are to be found in the Table. 
6.2.3. FACS analysis for the detection of NCR247 binding to the wholeC. trachomatis EBs 
To show that NCR247 is able to bind not only to the degraded Chlamydia particles but to 
the native, viable Chlamydia EBs, a FACS analysis was carried out. Figure 10 reveals that 
Chlamydia EBs interacted with FITC-conjugated NCR247 peptide. Untreated or FITC-labelled 
NCR035 peptide-treated (this peptide showed no anti-chlamydial effect earlier) Chlamydia EBs 
did not demonstrate increased fluorescence. 
  
Figure 10. FACS analysis of NCR247 peptide binding to whole C.  t rachomat i s  EBs. Untreated and unstained 
Chlamydia EBs (A). FITC-labelled NCR247 peptide treated C.  t rachomat i s  EBs (B). Chlamydia EBs treated with 
FITC-labelled NCR035 peptide (C). 
 7. Discussion 
Innate or natural immunity is the principal pathway for the effective elimination of most 
bacterial pathogens from the lung (Nelson et al., 1995). Antimicrobial peptides such as 
defensins are natural peptide antibiotics. When the host is challenged by microbes, these 
peptides act as the first line of innate defence before the activation of adaptive immunity. The 
defensins and certain chemokines, e.g. MIG/CXCL9, have similar characteristics, including 
size, disulphide bonding, IFN inducibility, a cationic charge at neutral pH, and the antimicrobial 
activity (Cole et al., 2001). Innate immune responses are enhanced in the presence of type 1 
cytokines, including IL-12 and IFN- (Moore et al., 2002; Rubins and Pomeroy, 1997). Type 1 
cytokine responses are indispensable for the effective killing of intracellular pathogens (Deng et 
al., 2001). Our aims were to reveal whether C. pneumoniae can induce the production of CXCL 
chemokines in vitro and in in vivo mouse model, and to detect the possible anti-chlamydial 
activity of CXCL chemokines in vitro. Our study revealed that C. pneumoniae can induce 
MIG/CXCL9 expression both in vitro and in vivo, and that MIG/CXCL9 has anti-chlamydial 
activity. Moreover, the potential chlamydial ligand of MIG/CXCL9 was suggested. 
The time course of the effect of IFN-, which is the main inducer of MIG/CXCL9 production 
following C. pneumoniae infection, was described earlier (Burian et al., 2003; Geng et al., 
2000). The in vivo kinetics of MIG/CXCL9 mRNA expression was similar to that of the 
recovery of viable Chlamydiae from the lungs after infection: the expression of the 
MIG/CXCL9 mRNA and the number of culturable Chlamydia inclusions were highest on day 
7, while at 4 weeks after infection the MIG/CXCL9 mRNA expression remained higher in the 
infected mice than in the controls, whereas the number of culturable C. pneumoniae inclusions 
had decreased to an undetectable level. The expression of IP-10/CXCL10 and I - TAC/CXCL1 
1 mRNA, in contrast with MIG/CXCL9 expression, peaked on day 4. The finding that IP-
10/CXC10 expression was highest on day 4 coincided with the result published by Maxion et 
al., that the level of IP-10/CXCL10 was highest on day 4 in the upper genital tract of mice after 
C. trachomatis infection (Maxion et al., 2002). The highest concentration of MIG/CXCL9 at a 
protein level was likewise observed on day 7. The Th1 cytokine IFN- plays important roles in 
combating acute Chlamydia infection and in the establishment of persistence (Rottenberg, 
2002). IFN- may also play a regulatory role in 
  
chlamydial defence, via its ability to alter the Th1/Th2 balance. Accordingly, IFN- gene knockout mice 
exhibited Th2-cytokine-dependent immunopathology together with disseminated chlamydial infection 
(Wang et al., 1999). IFN- may modify the outcome of infection by enhancing the expression 
of chemokines and adhesion molecules. IFN-administered therapeutically to patients with 
chronic granulomatous disease improved the ability of phagocytes to clear bacterial 
infections (Billiau and Matthys, 2009). Although there is still some controversy, it is quite plausible that 
the increase in antimicrobial activity results from oxygen-independent bactericidal mechanisms, including 
the IFN--inducible ELR-negative CXC chemokines. If, as might be expected, even higher concentrations 
prevail in the microenvironment of chemokine-secreting cells, antimicrobial effects could occur through 
the individual or combined activities of one or more of these chemokines. It is important that 
MIG/CXCL9 is not compartmentalized in the lungs, since we detected it in the circulation between days 7 
and 14 after C. pneumoniae infection, which suggests an important role of MIG/CXCL9 in the resolution 
of the infection. An elevated MIG/CXCL9 content has also been measured in the human plasma 
duringBurkholderia pseudomallei infection (Lauw et al., 2000). 
We found that in vitro infection with C. pneumoniae induced MIG/CXCL9 production from day 
3 in J774A cells, and from day 2 in infected mouse fibroblasts. It is interesting that mouse 
fibroblasts produced significantly more MIG/CXCL9 than did the macrophage cell line J774A 
(Figure 4A,B). It has been reported that cellular processes of non-immune cells (epithelial and 
endothelial cells and fibroblasts) triggered by chlamydial infection provoke the influx of 
inflammatory neutrophils, T cells, B cells and macrophages stimulated by the milieu of pro-
inflammatory cytokines and chemokines (Stephens, 2003). It was surprising that co-treatment of 
the mouse fibroblasts with a dose ofC. pneumoniae, which was unable to induce MIG/CXCL9 
production on day 1, and with 10 U of IFN- resulted in a 51.8-fold increase in MIG/CXCL9 
release as compared with treatment with 10 U of IFN- alone. Our observation that heat-
inactivated C. pneumoniae together with IFN- induced a 75-fold increase in MIG/CXCL9 
secretion relative to IFN- treatment alone suggests the heat-stable LPS as the putative 
chlamydial component responsible for the stimulation of MIG/CXCL9 production. Besides the 
respiratory C. pneumoniae strain CWL029, the cardiovascular strain CV6 was shown to 
stimulate the production of MIG/CXCL9. Similarly to our results, Högdahlet al. 
 
 found that C. pneumoniae T45, a respiratory strain isolate, induces the production of 
chemokines such as IL-8, MCP-1, RANTES, IP-10 and MIG/CXCL9 in human coronary artery 
endothelial cells after 48 h (Högdahl et al., 2008). 
Our experiments demonstrated that recombinant MIG/CXCL9 can inhibitC. pneumoniae in a 
dose-dependent manner. A previous work has revealed that MIG/CXCL9 and IP-10/CXCL10 
bear antibacterial effect against Escherichia coli and Listeria monocyto genes (Cole et al., 
2001). It was recently reported that CXCL9, CXCL10 and CXCL1 1 kill Streptococcus pyo 
genes, and that, in particular, CXCL9 was produced in a bactericidal concentration by inflamed 
pharyngeal cells both in vivo and in vitro (Egesten et al., 2009). The role of MIG/CXCL9 during 
bacterial infection has not been fully elucidated. In contrast with the examples mentioned above, 
in the case of Fine goldia magna MIG/CXCL9 displays no antibacterial activity. Moreover, the 
SufA of F. magna cleaves MIG/CXCL9 (Karls son et al., 2009, Karlsson et al., 2007). In our in 
vivo experiments, MIG/CXCL9 concentration in the whole lung suspension in the ELISA test 
was lower than the lowest bactericidal concentration in the in vitro test, but the local chemokine 
concentration should be higher in the affected area of the lung. Indeed, as MIG/CXCL9 has 
affinity for heparin, the local concentration might be even higher. Thus, interactions with 
glucosaminoglycans (GAGs) can retain MIG/CXCL9 at epithelial surfaces and further increase 
the local concentration. It has been suggested that the binding of chemokines to GAGs may 
furnish a chemotactic gradient to recruit leukocytes during inflammation (Egesten et al., 2007; 
Handel et al., 2005). Since MIG/CXCL9 was antichlamydial only when it was co-incubated (for 
at least 15 min) with the EBs, it is likely that the expressed MIG/CXCL9 does not exert an 
effect on already infected epithelial cells, but rather prevents the spread of infectious EBs 
extracellularly. 
By means of mass spectrometry, we identified three kinds of chlamydial proteins. We found that 
MIG/CXCL9 binds to OmcB, which has been identified as a major component of the 
chlamydial outer membrane complex, and is conserved among all chlamydial species (Wagels et 
al., 1994). OmcB was initially thought to be an intimate part of the outer membrane fraction of the 
chlamydial outer membrane complex. However, according to others, OmcB was resistant to 
trypsin digestion, which supported its lack of surface exposure (Everett and Hatch, 1995). 
Nonetheless, Moelleken and Hegemann established a yeast adhesion system in which the 
binding of live OmcB-presenting yeast cells to human cells could be studied. They 
 showed that the OmcB protein from C. pneumoniae mediates adhesion to HEp-2 cells 
(Moelleken and Hegemann, 2008). Moreover, OmcB induces a strong antibody response 
suggesting that it is readily accessible to the humoral immune response, which is indicative o a 
surface localization (Cunningham and Wards, 2003; Portig et al., 2003). Since OmcB protein is 
present on the surface, MIG/CXCL9 can bind to it. This is supported by our finding that the 
truncated form of OmcB (the 30 kDa protein) was the other protein identified by LCMSMS. 
During the denaturation process for the binding assay, this intermediate form of OmcB could be 
released from the EBs. Our results are also in accordance with MIG/CXCL9 having affinity for 
heparin (Handel et al., 2005). It is interesting that heparin-like (GAG) structures on the 
mammalian cell surface play an important role in the interactions with many bacterial pathogens 
and are recognized by chlamydial OmcB (Moelleken and Hegemann, 2008). Moreover, the M1 
protein, the major surface protein of S. pyo genes, which is necessary for the adhesion of bacteria 
to epithelial cells via GAGs, induces an enhanced production of MIG/CXCL9 (Eliasson et al., 
2007 and 2010). The third protein identified by mass spectrometry is the putative GroEL protein 
of C. pneumoniae. Wuppermann et al. recently described the localization of GroEL1 on the 
surface of the EBs, and the ability of GroEL1 to bind to MIG/CXCL9 therefore cannot be 
excluded (Wuppermann et al., 2008). Since our results showed that MIG/CXCL9 binds not only 
to the full OmcB protein, but also to its truncated form, and the role of OmcB protein in the 
initiation of infection is well documented, we concluded that binding to this protein is of major 
significance. 
Our FACS experiment confirmed that MIG/CXCL9 binds not only to the denatured proteins of 
the EBs, but also to the viable native form, supporting the antibacterial capability of this 
chemokine. 
Overall, these results indicate that C. pneumoniae has the capability to induce the production of 
MIG/CXCL9, IP-10/CXCL10 and I-TAC/CXCL1 1 in vivo, and the production of MIG/CXCL9 
in vitro. MIG/CXCL9 production did not require the presence of viable Chlamydiae. Our work 
was the first report about the anti-chlamydial activity of recombinant MIG/CXCL9, and about 
the role of the 60 kDa proteins in the binding of MIG/CXCL9 to the chlamydial cells. Thus, 
MIG/CXCL9 released by sentinel and non-immune cells could directly target and inactivate 
microbial pathogens, while also serving as a signal for the recruitment of leukocytes to infected 
tissues. 
 Because of the severity of C. trachomatis-caused infections and their consequences we 
were concerned about searching for new anti-chlamydial compounds. As mentioned above, C. 
trachomatis is the leading cause of sexually transmitted bacterial diseases in both developed 
and developing countries, with more than 90 million new cases of genital infections occurring 
annually. The development of effective new antimicrobial compounds is indispensable to avoid 
the late severe sequelae of the infections, such as ectopic pregnancy and infertility (WHO, 
1996). AMPs appear to be potentially promising candidates for this purpose. It was 
demonstrated that the synthetic tomato defensin peptide exhibits potent antibacterial activity 
against Gram-positive bacteria, such as Staphylococcus. aureus A170, Streptococcus. 
epidermidis, and Listeria. monocyto genes, and Gram-negative bacteria, including Salmonella 
enterica serovar Paratyphi, E. coli, and Helicobacter pylori (Rigano et al., 2012). In addition, 
the synthetic peptide shows minimal (<5%) hemolytic activity and absence of cytotoxic effects 
against THP-1 cells. Although their antimicrobial activity against bacteria, fungi and protozoa 
has been extensively studied (Rigano et al., 2012), their anti-chlamydial action has not yet been 
tested. In the present study, therefore, we investigated the in vitro activity of 11 NCR peptides 
against C. trachomatis. Seven of these peptides exerted significant antichlamydial activity at a 
10 g/ml concentration. A number of synthetic NCR peptides from Medicago truncatula have 
been reported to be potent killers of various Gram-negative (Escherichia coli, Salmonella 
Typhimurium, Agrobacterium tumefaciens, Pseudomonas aeruginosa and Xanthomonas 
campestris) and Gram-positive (Bacillus megaterium, Bacillus cereus, Clavibacter 
michiganensis, Staphylococcus aureus and Listeria monocyto genes) bacteria, including 
human/animal and plant pathogens (Tiricz et al., 2013). Furthermore, AMPs were effective 
against Staphylococcus epidermidis in in vivo mouse model, and they also displayed anti-
inflammatory activity (Capparelli et al., 2012). 
Our LC-MSMS experiment identified the GroEL protein of C. trachomatis as the 
chlamydial ligand of the NCR247 peptide. The GroEL protein is one of the few proteins that 
have so far been confirmed as relevant in chlamydial pathogenesis; it is also referred to as heat 
shock protein 60 (Hsp60) (Ward, 1999). This protein belongs to group I chaperones produced 
by almost all prokaryotic and eukaryotic cells, which assist as intracellular proteins, in the 
correct folding of nascent or denatured proteins under both normal and stress conditions (Zügel 
and Kaufmann, 1999). Several reports have indicated that molecular chaperones 
 produced by pathogenic bacteria, can function as intracellular, cell surface, or extracellula 
signals in the course of infection processes (Henderson et al., 2006). The immune responses to 
chlamydial GroEL correlate significantly with disease sequelae in humans, and 80 to 90% of 
patients infected with C. trachomatis have antibodies directed against GroEL (Horner et al., 
1997). The high degree of antigenicity of GroEL in patients implies that the protein i easily 
accessible to the immune system, perhaps becauseit is localized on the surface of the 
chlamydial particles. Early studies on isolated outer membrane complexes from C. trachomatis 
and C. psittaci EBs had indeed pointed to the possibility that GroEL might be associated with 
chlamydial membranes (Bavoil et al., 1990). Taken together, GroEL is accessible for the 
binding of NCR247 peptide. 
Our study indicates that certain NCR peptides possess substantial in vitro activity against 
C. trachomatis D. Studies of chlamydial infection in animal models are clearly needed to 
establish whether they have parallel in vivo results and whether these peptides can be useful lead 
compounds for the development of anti-chlamydial drugs. 
 The following of our results are considered novel 
1. We found that MIG/CXCL9 showed dose-dependent anti-chlamydial activity in in vitro C. 
pneumoniae infection. 
2. During our experiments it was revealed that the 60 kDa chlamydial proteins were 
responsible for the binding of MIG/CXCL9. 
3. Seven of the NCR peptides examined showed dose dependent anti-chlamydial effect in in 
vitro C. trachomatis infection. 
4. We found the chlamydial GroEL protein to be responsible for the binding of NCR247 
peptide. 
 8. Summary 
Chlamydophila pneumoniae and Chlamydia trachomatis are obligate intracellular 
parasites that belong to the family of Chlamydiaceae. These bacteria have the ability to cause 
prolonged and often subclinical infections. 
C. pneumoniae causes approximately 10% of community-acquired pneumonia cases among 
adults. Although most of the acute infections with C. pneumoniae are probably asymptomatic, 
they may be frequently associated clinically with pneumonia and bronchitis; moreover, C. 
pneumoniae infections have also been linked to the development of heart diseases and 
atherosclerosis. 
C. trachomatis has three human serotypes. Serovars D-K cause sexually transmitted diseases, 
which are of great public health significance. Cervicitis and urethritis commonly occur in 
women and about 40% of the untreated cases progress to pelvic inflammatory disease (PID). 
Infertility is the result in 20% of the PID cases, while 18% of the women with this disease 
experience chronic pelvic pain, and 9% may suffer an ectopic pregnancy. At the individual 
level, the diseases caused by C. trachomatis can generally be treated effectively with 
antibiotics, but at the population level, public health control of the infections is rather 
problematic. Vaccination, which is currently unavailable, would be the best way to reduce the 
prevalence of C. trachomatis infections, as it would be much cheaper and more effective in 
controlling chlamydial diseases. C. trachomatis has been reported to adopt an intracellular form 
that is metabolically less active and thus less sensitive to antibiotics. The development of new 
antimicrobial agents is required for the effective treatment of persistent chlamydial infections. 
CXC chemokines that lack the ELR (glutamic acid-leucine-arginine) motif, including the 
monokine induced by IFN- (MIG/CXCL9), the IFN-induced protein of 10 kDa (IP-
10/CXCL10), and the IFN-inducible T-cell -chemoattractant (ITAC/CXCL1 1), have been 
shown to mediate the generation of type 1 immune responses and to possess defensin-like 
bactericidal effects. Our study revealed that the infection of mice with C. pneumoniae via the 
intranasal route resulted in the local expression of MIG/CXCL9, IP-10/CXCL10, and I - 
TAC/CXCL1 1. MIG/CXCL9 was also detected at a protein level from day 1, with the highest 
concentration in the supernatants of the infected lungs on day 7. The expression of IFN-
displayed similar kinetics. C. pneumoniae and its inactivated form also induced the 
 
 production of MIG/CXCL9 in mouse fibroblasts and in the murine macrophage cell line J774A 
in vitro. Co-treatment of the tissue cultures with C. pneumoniae and different quantities of IFN- 
resulted in strong increases in MIG/CXCL9 production. Recombinan MIG/CXCL9 exerted 
dose-dependent antibacterial activity against C. pneumoniae. In our in vivo experiments, 
MIG/CXCL9 concentration in the whole lung suspension in the ELISA test was lower than the 
lowest bactericidal concentration in the in vitro test, but the local chemokine concentration 
should be higher in the affected area of the lung. Since MIG/CXCL9 seemed to bear anti-
chlamydial effect only when it was co-incubated (for at least 15 min) with the EBs, it is likely 
that the expressed MIG/CXCL9 does not exert an effect on already infected epithelial cells, but 
rather prevents the spread of infectious EBs extracellularly. Chlamydial proteins at a molecular 
weight of 60 kDa were identified by Far-Western blot assay and liquid chromatography-tandem 
mass spectrometry as binding molecules of MIG/CXCL9. The results of these experiments 
suggest that MIG/CXCL9 might play an important role in the innate and acquired defence 
mechanisms against C. pneumoniae. Antimicrobial peptides (AMPs) are natural antibiotics 
produced by nearly all organisms, from bacteria to plants and animals. Most plant AMPs are 
cysteine cluster proteins. This group includes major plant immunity effectors such as defensins, 
and also symbiotic peptides, including the nodule-specific cysteine rich (NCR) peptides. Some 
cationic NCRs have been shown to possess genuine antimicrobial activities in vitro, killing 
various Gram-negative and Gram-positive bacteria highly efficiently. In our present study, 7 of 
the 11 NCR peptides examined displayed dose- and time-dependent anti-chlamydial activity in 
vitro. NCR247 was demonstrated to bind to the 60-kDa putative GroEL protein of C. 
trachomatis. 
 9. Összefoglalás 
A Chlamydophila pneumoniae és Chlamydia trachomatis a Chlamydiaceae családba 
tartozy obligát intracellularis paraziták. Ezen baktériumok gyakran elhúzydy, tünetmentes 
fertőzéseket hoznak létre. 
A C. pneumoniae felelős a felnőttek közösségben szerzett tüdőgyulladásának kb. 10%-áért. 
Habár az akut fertőzések nagy része valyszínűleg tünetmentes, a betegség manifesztálydhat 
pneumonia vagy bronchitis képében; sőt, a C. pneumoniae által okozott infekciyknak szerepük 
lehet egyes szívbetegségek és az atherosclerosis kialakulásában is. 
A C. trachomatis-nak három human szerotípusa ismert. A D-K szerovariánsok szexuális úton 
átvihető fertőzéseket okoznak, amelyeknek népegészségügyi jelentősége kiemelkedő. Nőknél a 
fertőzés gyakran cervicitist és urethritis t okoz, amelyek kezeletlen esetben 40%-ban 
progrediálnak kismedencei gyulladássá (pelvic inflammatory dis ease, PID). A PID esetek 9%-
ában ectopiás terhesség, 18%-ában krynikus kismedencei fájdalom, 20%-ban terméketlenség a 
következmény. Habár egyéni szinten jyl kezelhetőek a C. trachomatis infekciyk, populáciys 
szinten rendkívüli nehézséggel jár a fertőzések kordában tartása. A jelenleg még nem elérhető 
vakcináciy lenne a leghatékonyabb mydszer a C. trachomatis által okozott betegségek 
prevalenciájának csökkentésére. Mivel a C. trachomatis képes egy metabolikusan kevéssé 
aktív és így az antibiotikumokra fokozottan rezisztens formában túlélni a sejten belül, új 
antimikrobiális szerek kifejlesztése kiemelkedően fontos. 
Az ELR (glutaminsav-leucin-arginin) motívumot nem tartalmazy CXC chemokinek, így a 
MIG/CXCL9 (monokine induced by IFN- az IP-10/CXCL10 (IFN-induced protein of 10 kDa), 
és az ITAC/CXCL1 1 (IFN-inducible T-cell -chemoattractant) az 1-es típusú immunválasz 
kiváltásában játszanak szerepet, valamint defenzin-szerű baktericid hatással bírnak. 
Kísérleteink során egereket fertőztünk intranasalisan C. pneumoniae-val, amely hatására a 
MIG/CXCL9, IP-10/CXCL10, és I-TAC/CXCL11 lokálisan expresszálydott az egerek 
tüdejében. A fertőzés utáni első naptyl a MIG/CXCL9 protein szinten is detektálhaty volt, 
legmagasabb koncentráciyban a fertőzést követő 7. napon. Az IFN- expressziyja hasonly 
kinetikát mutatott. 
C. pneumoniae élő és elölt formája hatására in vitro is megindult a MIG/CXCL9 termelődés az 
általunk használt egér fibroblast és J774A macrophag sejtvonalban. A sejtkultúrák egyidejű 
kezelése C. pneumoniae-val és IFN- különböző koncentráciyival szignifikáns emelkedést 
 indukált a MIG/CXCL9 termelődésben. Az alkalmazott rekombin áns MIG/CXCL9 dyzis-
dependens antibakteriális hatással rendelkezett a C. pneumoniae-val szemben. In vivo 
kísérleteinkben a MIG/CXCL9 kon cen tráciyja alacson yabb volt, min t azin vitro tesztekben 
hatásos koncentráciy, de a lokális chemokin szint valyszínűleg magasabb az érintett 
tüdőterületeken. Mivel a MIG/CXCL9 csak akkor mutatott anti-chlamydialis aktivitást, ha 
legalább 15 percig együtt in kubáltuk a chlamydia elementáris testekkel, valyszínűsíthető, hogy 
az expresszált MIG/CXCL9 nem a már fertőzött sejteken fejti ki hatását, han em 
extracellularisan akadályozza a fertőző elementáris testek terjedését. 
Far- Wes tern blot és LC-MSMS (folyadékkromatográfia-tömegspektrometria) vizsgálat során 
60 kDa molekulatömegű chlamydialis fehérjéket azonosítottunk a MIG/CXCL9 kötő 
partnereként. Ezen eredmények azt sugallják, hogy a MIG/CXCL9 fontos szerepet játszhat 
mind a veleszületett, mind pedig a szerzett anti-chlamydialis védekező mechanizmusokban. 
Az antimikrobialis peptidek olyan természetes anitibiotikumok, amelyek termelésére rengeteg 
élő szervezet képes, a baktériumoktyl anövényeken át az állatokig. A legtöbb antimikrobialis 
peptid ciszteinben gazdag fehérje. Ebbe a csoportba tartoznak olyan kiemelkedően fontos 
növényi immunitást szabályzy fehérjék, mint a defenzinekvagy a gümő-specifikus cisztein-
gazdag (Nodule-specific Cysteine-Rich, NCR) peptidek. Néhány kationos NCR ismert 
antimikrobiális hatással rendelkezik in vitro Gram-negatív és Gram-pozitív baktériumokkal 
szemben. Kísérleteink során 7 növényi peptid fejtett ki dyzis-, valamint időfüggő anti-
chlamydialis hatást in vitro. Az NCR 247 peptid kötő partnereként a C. trachomatis 60 kDa 
molekulatömegű GroEL fehérjéjét azonosítottuk. 
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